

Appendix E.

Proportion of patients achieving ASAS responses (20% and 40%) with CT-P13 (5 mg/kg) or INX (5 mg/kg) at week 14 and week 30 in the all randomised population (CT-P13: N=125; INX: N=125).

Figure S2-1. ASAS20 rates at weeks 14 and 30




Figure S2-2. ASAS40 rates at weeks 14 and 30

